MEDIPOST obtained Singpore patent for the technology of cartilage differentiation of cord blood originated stem cell which is used as raw material for arthritis treatment drug ‘CARTISTEM^®’

MEDIPOST obtained patent in Sinpore on 18 March for ‘TSP-1, TSP-2, IL-17BR and HB-EGF associated with stem cell activities and applications thereof’

This patent relates to the technology which confirms that the cultivated stem cells adjust differentiation of cartilage cells and inhibit their destruction by excreting proteins such as TSP-1, TSP-2, IL-17BR, HB-EGF.

MEDIPOST personnel stated that “because the difference in cartilage differentiation ability of each cell can be confirmed with this patented technology, it can be utilized for selection of cells to be used as raw mateiral in the manufacturing process for ‘CARTISTEM^®’ and appears to help with quality maintenance and improvement of therapeutic efficacy of ‘CARTISTEM^®’.